Cell Therapies, Cancer & Rare Diseases

Cell Therapies, Cancer & Rare Diseases
  • Pininvest Analysis

Cell therapies have opened new treatment fields by cell inhibitors, gene modification, or even gene replacement

By gene modification after extraction of white blood cells from a leukemia-fighting patient, the cells are bolstered for more vigorous attack of cancer cells and reinjected in the patient; the Novartis treatment researched by University of Pennsylvania has been approved by the FDA in August ’17 and more than 76 applications have been accepted for testing in this promising field, possibly extending the procedure to some forms of brain and lung cancer patients - Check our note "Immunotherapy by adaptive cell transfer (ACT)' for more information

Gene replacement aims disease caused by a single faulty gene and the first treatment, targeting vision loss due to genetic mutation, introduced by Spark Therapeutics, is the first of its kind to be approved by FDA (December ’17)

Read our notes

Cell Therapies, Cancer & Rare Diseases • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Vol. Risk Contrib. MDD
 
Adaptimmune Therapeutics ADAP NASDAQ Health Care Biopharmaceuticals USD 7.98 1.2 B 303.0% 167%   6% -34%
Amgen Inc. AMGN NASDAQ Health Care Biopharmaceuticals USD 240.69 141 B 33.2% 36%   2% -25%
Bellicum Pharmaceuticals BLCM NASDAQ Health Care Biopharmaceuticals USD 7.06 36 M -40.2% 131%   5% -85%
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 63.48 4.2 B -49.0% 67%   4% -68%
Celgene CELG NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 108.24 77 B 13.6% 6%   0% -3%
Cellectis (ADR) CLLS NASDAQ Health Care Gene Editing - Cell Therapies USD 17.49 743 M 26.2% 77%   4% -60%
Celyad (ADR) CYAD NASDAQ Health Care Biopharmaceuticals USD 10.28 143 M -22.3% 104%   4% -72%
Clovis Oncology, Inc. CLVS NASDAQ Health Care Biopharmaceuticals USD 5.42 417 M -7.0% 137%   6% -77%
Corvus Pharmaceuticals CRVS NASDAQ Health Care Biopharmaceuticals USD 4.25 119 M 18.7% 124%   5% -71%
CRISPR Therapeutics CRSP NASDAQ Health Care Gene Editing - Cell Therapies USD 89.81 6.3 B 83.1% 64%   4% -54%
Editas Medicine EDIT NASDAQ Health Care Gene Editing - Cell Therapies USD 34.71 1.9 B 40.1% 71%   4% -55%
Gilead Sciences GILD NASDAQ Health Care Biopharmaceuticals USD 69.35 87 B 11.0% 38%   1% -18%
Immunogen IMGN NASDAQ Health Care Biopharmaceuticals USD 4.06 708 M 42.8% 98%   5% -69%
Intellia Therapeutics NTLA NASDAQ Health Care Gene Editing - Cell Therapies USD 19.83 1.2 B 12.3% 81%   5% -47%
Intercept Pharmaceuticals ICPT NASDAQ Health Care Biopharmaceuticals USD 48.75 1.6 B -26.2% 85%   4% -65%
Invitae NVTA NYSE Health Care Gene Editing - Cell Therapies USD 28.43 3.7 B 3.4% 98%   6% -72%
MacroGenics MGNX NASDAQ Health Care Biopharmaceuticals USD 27.42 1.5 B 88.3% 148%   6% -72%
NantKwest, Inc. NK NASDAQ Health Care Biopharmaceuticals USD 10.52 1.0 B 685.1% 140%   6% -32%
Neos Therapeutics NEOS NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 0.72 36 M -56.6% 78%   3% -67%
Novartis NVS NYSE Health Care Drug Manufacturers - Diversified USD 82.91 188 B -5.8% 28%   1% -29%
Regeneron Pharmaceuticals REGN NASDAQ Health Care Biopharmaceuticals USD 620.21 66 B 100.2% 41%   1% -13%
REGENXBIO RGNX NASDAQ Health Care Gene Editing - Cell Therapies USD 33.02 1.2 B -20.1% 76%   5% -60%
Sangamo Therapeutics SGMO NASDAQ Health Care Gene Editing - Cell Therapies USD 12.33 1.7 B 3.0% 71%   4% -58%
Spark Therapeutics ONCE NASDAQ Health Care Biopharmaceuticals USD 113.57 4.4 B 11.6% 13%   0% -9%
uniQure QURE NASDAQ Health Care Gene Editing - Cell Therapies USD 41.30 1.8 B -26.3% 65%   3% -49%
Vericel VCEL NASDAQ Health Care Gene Editing - Cell Therapies USD 15.74 712 M -14.2% 67%   3% -62%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 3.32 711 M -41.5% 79%   4% -67%